Abstract
Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have